Business Wire

VA-DXC-TECH/TOPSAIL-RE

2.9.2020 15:02:08 CEST | Business Wire | Press release

Share
Topsail Re Selects DXC Technology’s End-to-End Reinsurance Administration Platform

Topsail Re, a recent entrant into the global reinsurance market, has selected DXC Technology (NYSE: DXC) to deploy an end-to-end solution supporting the complete reinsurance life cycle.

Topsail Re is deploying the DXC SICS solution — a leading reinsurance management platform implemented on Amazon Web Services (AWS) — to help manage their book of business. This will include treaty management, improving claims administration, ensuring accuracy with accounting transactions and reducing operational costs to support anticipated expanded growth.

“One of the core aspects of our business strategy is simplifying the reinsurance process for all parties and providing our partners with a stable, long-term platform,” said David Johnson, chairman and chief executive officer, Topsail Re. “DXC’s solution was the most comprehensive application of its kind and will save time and reduce costs through automation, as well as provide the reporting tools we need to meet regulatory requirements.”

The DXC SICS platform is a core administration system that provides comprehensive automation across the complete reinsurance management life cycle. The solution streamlines reinsurers’ processing needs, from new business to renewal management and accounting to retrocession. DXC’s SICS platform has been deployed by more than 100 insurance and reinsurance companies globally.

“DXC is focused on helping Topsail Re optimize their reinsurance management life cycle as they continue to seize new business opportunities,” said Phil Ratcliff, vice president and general manager, Global Insurance, DXC Technology. “Deployment of the DXC SICS solution will deliver the end-to-end platform Topsail Re requires and enable them to better serve customers.”

DXC is a leading provider of core insurance systems, serving more than 80% of insurers in the Fortune Global 500.

For more information on DXC’s SICS platform, click here . To learn more about DXC services and solutions for the insurance industry, visit www.dxc.technology/insurance .

About Topsail Re

Topsail Re is a closely held reinsurer domiciled in the Cayman Islands with affiliated offices in Greensboro, NC and Schaumburg, IL. Their strategy is to be disciplined and patiently develop long-term profitable relationships with companies that are like minded. Currently, Topsail Re writes in excess of $300M in premium income and is expanding its infrastructure to facilitate highly controlled growth.

Learn more about Topsail Re, visit www.topsailre.com .

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy the Enterprise Technology Stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OpZira, Inc. Welcomes Scott Thielman, PhD, as Vice President of Product Development30.6.2026 13:17:00 CEST | Press release

OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced that Scott Thielman, PhD, PE, has joined the company as Vice President of Product Development, effective May 1, 2026. Dr. Thielman brings a unique connection to OpZira’s origins. As Chief Technology Officer of Product Creation Studio, he directed the product development of LumiThera’s Valeda® Light Delivery System - the breakthrough photobiomodulation therapy for dry age-related macular degeneration whose acquisition by Alcon led to the creation of OpZira. His involvement with Valeda gives him firsthand knowledge of the science, clinical vision, and engineering decisions that shaped the technology platform from which OpZira was born. For more than 25 years, Dr. Thielman has directed the development of dozens of FDA-cleared medical devices across ophthalmology, neurostimulation, dermatology, urology, and surgical instrumentation, with partners including Olympus

L&T Technology Services Launches Ainfonix™ 4.0 to Unlock Engineering Intelligence Across Process Industries30.6.2026 12:45:00 CEST | Press release

The enterprise AI platform turns millions of engineering artifacts that run a plant into accurate, decision-ready data, delivering up to 85% extraction accuracy and full, audit-ready traceability L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced the launch of Ainfonix™ 4.0, a next-generation Engineering Intelligence platform for process industries. Unveiled at EI Live, LTTS’ flagship event that brings together analysts, industry leaders and engineering experts, Ainfonix™ 4.0 marks an important step in the company’s Enterprise AI and Engineering Intelligence strategy. As industrial enterprises accelerate AI adoption, decades of engineering knowledge remain trapped in fragmented drawings, specifications and technical records across disparate systems. Without trusted and accessible engineering data, organizations struggle to realize the full value of AI, automation and digital transformation

Klick Health Acquires Oxford PharmaGenesis, Bringing Together Unsurpassed Scientific-to-Commercial Capabilities for Life Sciences Clients30.6.2026 12:03:00 CEST | Press release

Bonded by breakthroughs and a laser focus on their people and clients, leading independent agencies join forces to deliver accelerated commercial success through broadened medical affairs and communications, market access, and RWE/HEOR offerings; the most advanced degree holders; expanded global reach; and the best workplace culture around Focused on taking life sciences companies into the future, Klick Health today announced its acquisition of Oxford PharmaGenesis, the market-leading HealthScience communications consultancy renowned for its scientific and medical expertise, as well as value and market access consulting throughout Europe, Asia-Pacific, and North America. Today’s news brings together two of the leading independent agencies in life sciences. With Oxford PharmaGenesis’ expertise across medical affairs and market access, and Klick's strength in commercial strategy, medical, creative, digital, analytics, and experience design, they can deliver an unparalleled scientific-to-

BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma30.6.2026 12:00:00 CEST | Press release

Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), meeting the primary endpoint of PFSMANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusionsFull results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating foundational BTK inhibitor BRUKINSA® (zanubrutinib) plus rituximab versus bendamustine plus rituximab (BR) in adult patients with previously untreated mantle cell lymphoma (MCL). MANGROVE is the first Phase 3, global, randomized trial to evaluate a BTK inhibitor-based chemotherapy-

Hytera Debuts SC700 Smart 4G Body Camera at CCW 202630.6.2026 11:30:00 CEST | Press release

Hytera, a leading global provider of critical communications technologies and solutions, officially debuted its SC700 Smart 4G Body Camera at Critical Communications World (CCW) 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630283236/en/ Hytera's latest SC700 Smart 4G Body Camera Public safety operations are increasingly moving toward real-time, connected workflows, where communication, video, and situational awareness are integrated to support a faster and more coordinated response in the field. The SC700 is designed to support this shift. It enables live video, location sharing and push-to-talk communication, helping connect frontline officers with control rooms. Integrated with Hytera HyTalk PoC System, it also supports communication across broadband and PMR users to improve coordination across teams. It also features Intelligent Scene Aware, which can detect abnormal situations such as man down, inactivity, or

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye